Current Therapeutic Research-clinical and Experimental最新文献

{"title":"Surgical Antibiotic Prophylaxis Used in A University Clinics Hospital and Antibiotic Costs: A 3-year Survey","authors":"Vianney N. Ntabaza PhD ,&nbsp;Antonelle Pardo PhD ,&nbsp;Amandine Nachtergael PhD ,&nbsp;Julien Bamps MSc ,&nbsp;Salvius A. Bakari PhD ,&nbsp;Pierre Duez PhD ,&nbsp;Stephanie Patris PhD ,&nbsp;Byanga Kahumba PhD","doi":"10.1016/j.curtheres.2025.100807","DOIUrl":"10.1016/j.curtheres.2025.100807","url":null,"abstract":"<div><h3>Background</h3><div>Surgical Site Infections (SSIs) represent one of the most common post-operative complications and are the third most prevalent nosocomial infections.</div></div><div><h3>Objective</h3><div>The objective of this study was to analyze the conditions of using antibiotics in surgery at the University Clinics of Lubumbashi.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted, collecting data from medical registers over a 3-year period, from 2017 to 2019. Parameters have been analyzed according to the European Centre for Disease Prevention and Control (ECDC), National Institute for Health and Care Excellence (NICE) and World Health Organization (WHO) guidelines.</div></div><div><h3>Results</h3><div>Shortcomings in registered data and the application of exclusion criteria allowed to include only 256 of the 977 retrospective procedures recorded during this period, with around 50% of the cases in 2019. A little more than half of them concerned men with a sex ratio of 1.28. Among these patients, 66% were aged between 16 and 40 years. Of these, 37.1% underwent visceral surgery. Over 38.7% of patients were hospitalized for more than 30 days, with 4.3% staying over 4 months. After the surgery, metronidazole 1.5 g, ceftriaxone 1 g and cefotaxime 1 g were the most used (89%) antibiotics followed by amoxicillin 1 g, all mainly parenterally. In 38,7% of cases, a series of other antibiotics were used in combination over a long period (7 days). A 32.8% rate of surgical site infection was recorded, with antibiotic-related costs of around 62,311 ± 30,417 CDF (31 ± 15 €). A comparison of the characteristics of patients with and without infections showed a significant influence of the sex and type of surgery. Men were 4.7 times more likely to develop a surgical site infection than women, and orthopedic surgery had a higher risk of infection than other surgeries.</div></div><div><h3>Conclusion</h3><div>These retrospective data suggest that the use of antibiotics before and after surgery at the University Clinics of Lubumbashi does not meet accepted standards (ECDC, NICE and WHO guidelines) and would not be efficient for their intended purpose.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100807"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Sublingual Immunotherapy in Patients With House Dust Mite Allergic Asthma—A Systematic Review","authors":"Pernille Vigand Hegner MSt ,&nbsp;Anne Sofie Rysgaard MSt ,&nbsp;Alma Holm Rovsing MD, PhD ,&nbsp;Charlotte Suppli Ulrik MD, DMSc, FERS","doi":"10.1016/j.curtheres.2025.100785","DOIUrl":"10.1016/j.curtheres.2025.100785","url":null,"abstract":"<div><h3>Background and objective</h3><div>Patients’ with allergy-driven symptoms of asthma may not achieve adequate symptom control on inhaled pharmacotherapy alone, therefore, allergen-immunotherapy may be a relevant add-on treatment. The aim of the present review is to provide an update on the current evidence of efficacy of sublingual immunotherapy (SLIT) for the treatment of house dust mite (HDM)-driven allergic asthma.</div></div><div><h3>Methods</h3><div>Systematic review performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses-Statement (PRISMA) guidelines.</div></div><div><h3>Results</h3><div>A total of 15 studies fulfilled the predefined criteria and were included, all assessing the efficacy of the HDM SLIT-tablet in patients with HDM-driven asthma. Of the 15 studies, 13 reported significant improvements in asthma symptoms, while 2 found no changes. Ten studies assessed lung function (that is FEV₁, PEF and FEV₁/FVC) with 6 reporting significant improvements and 4 reporting no significant changes. Eight of the 15 studies measured the impact on prescribed asthma controller medication, of which 6 studies reported a significant reduction in daily mean dose of inhaled corticosteroid (ICS) (up to a reduction of 300+ µg/day), 1 found a significant reduction in medication use (according to the GINA steps), while 1 showed no significant reduction.</div></div><div><h3>Conclusion</h3><div>In the majority of studies, HDM SLIT was associated with improvements in asthma symptom control and a reduction in daily dose of ICS. On the other hand, the findings addressing treatment induced changes in lung function are conflicting.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100785"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Dietary Acid Load and Risk of Metastatic Colorectal Cancer: A Case-Control Study","authors":"Fatemeh Babaee Kiadehi MSc ,&nbsp;Niayesh Naghshi MSc ,&nbsp;Fatemeh Farz MSc ,&nbsp;Pedram pam PhD ,&nbsp;Arash Tandorost MSc ,&nbsp;Alireza Ostadrahimi MD, PhD ,&nbsp;Reza Eghdam Zamiri MD","doi":"10.1016/j.curtheres.2025.100790","DOIUrl":"10.1016/j.curtheres.2025.100790","url":null,"abstract":"<div><h3>Purpose</h3><div>Colorectal cancer (CRC) is a type of cancer affecting the colon and rectum, primarily originating from intestinal polyps. Recently, increasing attention has been given to the role of dietary acid-base balance in cancer development. This study aimed to investigate the relationship between dietary acid load and the risk of metastatic colorectal cancer (mCRC).</div></div><div><h3>Design/methodology/approach</h3><div>This hospital-based case-control study was conducted on 120 adults with mCRC and 240 non-neoplastic adults in the control group, matched for age and gender. Dietary intake was assessed using a food frequency questionnaire. Net endogenous acid production (NEAP) and potential renal acid load (PRAL) were calculated using predetermined formulas. Odds ratios (ORs) were used to estimate the risk of mCRC across PRAL and NEAP tertiles.</div></div><div><h3>Findings</h3><div>There were no significant differences between the two groups in terms of demographic characteristics, anthropometric measures, smoking, and alcohol consumption. However, energy intake and energy-adjusted carbohydrate, fiber, potassium, magnesium, and calcium intake were significantly higher in the control group compared to the case group (<em>P</em> &lt; 0.05). The mean PRAL in the case group (10.5 ± 1 mEq/day) was significantly higher than in the control group (5.2 ± 0.5 mEq/day) (<em>P</em> &lt; 0.001). However, no significant difference was observed between the groups regarding NEAP (35 ± 7 mEq/day in the control group vs. 36 ± 5.5 mEq/day in the case group, <em>P</em> = 0.12). The second and third tertiles of PRAL were associated with an increased risk of mCRC compared to the first tertile (OR = 3.4, 95% CI: 1.6–7; OR = 4.1, 95% CI: 2–8.5, respectively) (<em>P</em> &lt; 0.001).</div></div><div><h3>Originality/value</h3><div>High PRAL levels were associated with an increased risk of mCRC, whereas NEAP scores were not linked to mCRC risk.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100790"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143918424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose Radiation Therapy (LDRT) in Managing Osteoarthritis: A Comprehensive Review","authors":"Armin Hoveidaei ,&nbsp;Mehdi Karimi ,&nbsp;Amirhossein Salmannezhad ,&nbsp;Yasaman Tavakoli ,&nbsp;Seyed Pouya Taghavi ,&nbsp;Amir Human Hoveidaei","doi":"10.1016/j.curtheres.2025.100777","DOIUrl":"10.1016/j.curtheres.2025.100777","url":null,"abstract":"<div><div>Osteoarthritis (OA) is the most common degenerative arthropathy, impacting the quality of life for millions worldwide. It typically presents with chronic pain, stiffness, and reduced mobility in the affected joints. Nonsurgical treatments like physiotherapy or pharmacotherapy may provide limited relief and may have adverse effects and complications. Recently, low-dose radiation therapy (LDRT) has emerged as a potential alternative for managing OA, utilizing its anti-inflammatory effects. LDRT's anti-inflammatory effects involve modulating immune responses, reducing pro-inflammatory cytokines, and inducing apoptosis in inflammatory cells. Clinical studies show varying degrees of symptom relief, with some patients experiencing pain reduction and improved joint mobility while others show minimal response. The variability in LDRT treatment designs, radiation dosages, and patient populations complicates standardized treatment protocols and raises concerns about potential carcinogenic risks. Despite these issues, LDRT shows promise as an alternative to other OA treatments, especially for patients who don't respond to other treatments. This review aims to provide updated information on the effectiveness, mechanisms, and safety of LDRT in treating OA. We reviewed the literature of studies on the safety and efficacy of LDRT on affected joints by OA, its biological effects, potential therapeutic and adverse effects, application and contraindications, clinical outcomes, and clinical evidence in subjects with OA.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100777"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143643986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioequivalence Study of Ibuprofen and Diphenhydramine Hydrochloride mini liquid-filled capsules: A Size Reduction Alternative","authors":"David J. Wyatt ,&nbsp;Mako Araga ,&nbsp;Natali McCloskey ,&nbsp;Richard Petruschke ,&nbsp;Marianna Armogida MD","doi":"10.1016/j.curtheres.2025.100779","DOIUrl":"10.1016/j.curtheres.2025.100779","url":null,"abstract":"<div><h3>Background</h3><div>Advil PM Liqui-Gels are widely used to improve the quality of life for individuals experiencing sleep disturbances due to pain. To accommodate those who have difficulty swallowing traditional capsules, Advil PM Liqui-Gels Minis, a smaller capsule variant containing the same composition (ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg) as the original Advil PM Liqui-Gels, was developed as a more manageable alternative.</div></div><div><h3>Objective</h3><div>Establish the bioequivalence of new size-reduced Advil PM Liqui-Gels Minis (test) compared to the currently marketed Advil PM Liqui-Gels (reference) product under fasting conditions.</div></div><div><h3>Method</h3><div>This Phase I study was a randomized, open-label, two-treatment, two-sequence, two-period crossover trial. Subjects either received a single dose of test or reference product, separated by a 7-days washout period. Primary endpoints included PK parameters (C_max, AUC_0-t, AUC_0-inf) for ibuprofen and diphenhydramine. Secondary endpoints were t_max, t_1/2, Cl/F, V_z/F, and λ_Z. Safety assessments covered adverse events, lab results, and physical exams.</div></div><div><h3>Results</h3><div>Forty-four subjects were randomized, 42 completed both treatment periods for ibuprofen and 41 for diphenhydramine. The population was balanced in age, BMI, and gender, predominantly Hispanic/Latino. Mean C_max values for test and reference products were comparable, with a median t_max of 3 hours for diphenhydramine (both test and reference) and 1 hour (test) and 0.875 hour (reference) for ibuprofen. The geometric mean ratios (90% CI) for all pharmacokinetic (PK) parameters (AUC_0-t, AUC_0-inf, and C_max) were 99.15% (96.76–101.61), 99.20% (96.82–101.63) and 95.13% (88.31–102.47), respectively, for ibuprofen, and 102.62% (98.15–107.30), 102.73% (98.31–107.34), and 102.51% (93.54–112.35), respectively, for diphenhydramine. All values fell within the bioequivalence acceptance criteria of 80%–125%. No serious adverse events were reported, and subjects rated the ease of swallowing positively for both formulations.</div></div><div><h3>Conclusion</h3><div>The new Advil PM Liqui-Gels Minis formulation is bioequivalent to the marketed Advil PM Liqui-Gels. The smaller capsule size may offer a more convenient option for individuals with swallowing difficulties, without compromising the drug's efficacy or safety.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100779"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of Contractility of Isolated Caprine Detrusor by the Rho Kinase Inhibitor Fasudil and Reversal by the Guanylyl Cyclase Inhibitor ODQ","authors":"Niranjana Jeba Jeeviha MD,&nbsp;Aniket Kumar PhD,&nbsp;Rohini Ann Mathew MD,&nbsp;Silvia Joseph MD,&nbsp;Mohammed Haris MSc,&nbsp;Margaret Shanthi MD,&nbsp;Jacob Peedicayil MD","doi":"10.1016/j.curtheres.2025.100795","DOIUrl":"10.1016/j.curtheres.2025.100795","url":null,"abstract":"<div><h3>Background</h3><div>Rho kinase (also called rho-associated protein kinase or ROCK), a serine/threonine kinase, is involved in muscle contractility since it phosphorylates myosin light chain phosphatase, hence inhibiting it. This leads to enhanced muscle contractility. Fasudil is an inhibitor of rho kinase that has been approved for the treatment of cerebral vasospasm in some Asian countries.</div></div><div><h3>Objective</h3><div>In this study, we tested the ability of fasudil to inhibit the contractility of the isolated caprine (goat) detrusor.</div></div><div><h3>Methods</h3><div>Twelve caprine detrusor strips were contracted using 80 mM KCl before and after the administration of 3 concentrations (10, 30, and 60 µM) of fasudil. Two reversal agents, the guanylyl cyclase inhibitor ODQ (10 µm) and the P2X receptor agonist diadenosine pentaphosphate (DAPP) (10 µM), were tested for their ability to reverse the inhibitory effect of fasudil on isolated detrusor contractility.</div></div><div><h3>Results</h3><div>Fasudil caused a dose-dependent inhibitory effect of KCl-induced detrusor contractility that was statistically significant at 30 and 60 µM concentrations. The inhibitory effect of 30 µM fasudil on detrusor contractility was significantly reversed by the addition of ODQ, but not by the addition of DAPP.</div></div><div><h3>Conclusions</h3><div>These results suggest that fasudil inhibits the contractility of the isolated detrusor. Fasudil could be investigated for use in clinical conditions such as overactive bladder that require detrusor muscle relaxation.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100795"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Biosimilar Aflibercept SDZ-AFL","authors":"Francis Dodeller PhD ,&nbsp;Peter Alliger PhD ,&nbsp;Jens Heyn MD ,&nbsp;Dragan Urosevic MD ,&nbsp;Lisa Allmannsberger PhD ,&nbsp;Cornelia Wersig PhD ,&nbsp;Rufino Silva MD, PhD","doi":"10.1016/j.curtheres.2025.100812","DOIUrl":"10.1016/j.curtheres.2025.100812","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;Aflibercept is a recombinant fusion protein that binds with high affinity to vascular endothelial growth factor A (VEGF-A), and other growth factors, reducing pathological neovascularization and abnormal vascular permeability. Aflibercept is approved as a first-line treatment for several retinal diseases, including neovascular age-related macular degeneration (nAMD); however, the high costs of these biologic agents can impede patient access. In 2024, Sandoz biosimilar aflibercept (SDZ-AFL; SOK583A1, Enzeevu/Afqlir) was approved by the US Food and Drug Administration and the European Medicines Agency as a biosimilar of reference aflibercept (Ref-AFL; Eylea, a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc) based on a comprehensive package of data.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This narrative review summarizes the totality of evidence demonstrating biosimilarity between SDZ-AFL and Ref-AFL, including physicochemical and biological characterization data from analytical in vitro studies, results of an ocular pharmacokinetic (PK) study in rabbits, and clinical efficacy, safety, immunogenicity, and systemic PK data from Phase III clinical studies.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Analytical evaluation demonstrated that SDZ-AFL has structural homology with Ref-AFL, including identical amino acid sequences, indistinguishable higher-order structures, and highly similar levels of structural variants. SDZ-AFL and Ref-AFL also demonstrated highly similar in vitro biologic activities&lt;em&gt;,&lt;/em&gt; including target binding affinity, and potency in terms of neutralization of VEGF-A. In a single-dose ocular PK study in rabbits, vitreal exposure was comparable between SDZ-AFL and Ref-AFL after intravitreal administration. A 52-week Phase III clinical study (Mylight) evaluated the efficacy, safety, immunogenicity, and systemic PK of SDZ-AFL and Ref-AFL in 484 participants with nAMD. The primary endpoint was mean change from baseline to week 8 in best corrected visual acuity (BCVA): the difference between the SDZ-AFL and Ref-AFL groups in this endpoint was –0.3 letters (90% CI −1.5 to 1.0), which met predefined bioequivalence margins. Secondary efficacy endpoints, including changes from baseline in BCVA and central subfield foveal thickness over the whole 52-week study, were also similar for SDZ-AFL and Ref-AFL. Two subsequent “in-use” studies confirmed the safe use of SDZ-AFL provided in either a vial kit or a prefilled syringe.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;This comprehensive totality of evidence has established biosimilarity between SDZ-AFL and Ref-AFL based on comparable physicochemical and biological characteristics, as well as similarity in clinical efficacy, safety, and immunogenicity. The introduction of aflibercept biosimilars to the market is anticipated to reduce barriers to access, potentially increasing the number of appropriate patients with retinal diseases benefiting from this biologi","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100812"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145154660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibitory effects of heat-killed lactic acid bacterium Enterococcus faecalis on the growth of Porphyromonas gingivalis","authors":"Tomoe Matsuo,&nbsp;Koji Nakao,&nbsp;Kosuke Hara","doi":"10.1016/j.curtheres.2024.100731","DOIUrl":"10.1016/j.curtheres.2024.100731","url":null,"abstract":"<div><h3>OBJECTIVES</h3><p>The effects of heat-killed <em>Enterococcus faecalis</em> (<em>HkEf</em>), a lactic acid bacterium, on the growth of <em>Porphyromonas gingivalis</em> were evaluated <em>in vitro</em> by measuring the viable cell count of <em>P. gingivalis</em> and gingipain activity.</p></div><div><h3>METHODS</h3><p><em>HkEf</em> solution (1.63 or 163 mg/mL) was added to 1 mL <em>P. gingivalis</em> culture to generate a final <em>HkEf</em> concentration of 0.64 or 64 mg/mL. The cultures were incubated anaerobically. The number of viable <em>P. gingivalis</em> cells and gingipain activity were measured after incubation for 0, 12, 24, 48, and 72 h. The number of viable <em>P. gingivalis</em> cells was calculated by counting the number of colonies after culture. Gingipain activity was quantified by adding a chromogenic substrate to <em>P. gingivalis</em> culture medium and measuring the absorbance of the reaction solution with a plate reader. Mean ± SE was calculated for viable cell counts and gingipain activity, and Wilcoxon rank sum test was used to test for significant differences.</p></div><div><h3>RESULTS</h3><p>The counts of viable <em>P. gingivalis</em> cells in the control group increased as incubation time progressed for 12, 24, 48, and 72 h; similar results were observed in the low-concentration <em>HkEf</em> group. In the high-concentration <em>HkEf</em> group, the increase in the viable cell count was significantly inhibited compared to that of the control group. Furthermore, gingipain activity in the low- and high-concentration <em>HkEf</em> groups was significantly inhibited over time compared to that of the control group. Although the pH of the culture solution tended to decrease in the high-concentration <em>HkEf</em> group, it was not considered to have affected the growth of <em>P. gingivalis</em>.</p></div><div><h3>CONCLUSIONS</h3><p><em>HkEf</em> exhibits inhibitory effects on the growth of <em>P. gingivalis</em> and gingipain activity.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100731"},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000018/pdfft?md5=8daa219505edcced8e3b6aeddc07ecbb&pid=1-s2.0-S0011393X24000018-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139883993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Ischemic Stroke in a Patient with Multiple Sclerosis after Initiating Teriflunomide Treatment: A Challenging Case","authors":"Arsh Haj Mohamad Ebrahim Ketabforoush MD ,&nbsp;Armin Tajik MD ,&nbsp;Mohammad Amin Habibi MD ,&nbsp;Nahid Abbasi Khoshsirat MD","doi":"10.1016/j.curtheres.2024.100732","DOIUrl":"https://doi.org/10.1016/j.curtheres.2024.100732","url":null,"abstract":"<div><p>Multiple sclerosis is an autoimmune disease of the central nervous system, during which vascular events, including atherosclerosis, are more common and progress faster. Teriflunomide (TFN) is an oral drug that studies have indicated has low side effects alongside high efficiency. In this article, a middle-aged woman with multiple sclerosis was introduced, whose medication was changed to TFN. Thirty-five days later, she presented with focal neurologic symptoms, and investigations reported a lacunar infarction. Having excluded potential causes of acute ischemic stroke, such as vascular and rheumatologic factors, the only identifiable factor was the introduction of a new medication. The process of conclusively attributing TFN as the causative agent requires further clarification in future studies.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100732"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X2400002X/pdfft?md5=5691a7209eda6840999a0100b284563f&pid=1-s2.0-S0011393X2400002X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139901310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of Propolis Consumption on Body Composition and Blood Pressure: A Systematic Review and Dose-Response Meta-Analysis","authors":"Mahdi Vajdi Ph.D ,&nbsp;Atefeh Bonyadian MSc ,&nbsp;Fatemeh Pourteymour Fard Tabrizi Ph.D ,&nbsp;Reza Hassanizadeh Ph.D ,&nbsp;Nooshin Noshadi MSc ,&nbsp;Beitullah Alipour Ph.D ,&nbsp;Mahdieh Abbasalizad-Farhangi Ph.D ,&nbsp;Melika Darzi MSc ,&nbsp;Sahar Golpour-Hamedani Ph.D ,&nbsp;Gholamreza Askari Ph.D","doi":"10.1016/j.curtheres.2024.100754","DOIUrl":"10.1016/j.curtheres.2024.100754","url":null,"abstract":"<div><h3>Introduction and Aim</h3><p>Research on the effects of propolis consumption on body composition, and blood pressure (BP) has produced inconsistent results. This systematic review and dose-response meta-analysis was carried out to compile the data from the randomized controlled trials (RCTs) on how propolis supplementation affects body composition, and BP level in adults.</p></div><div><h3>Materials and Methods</h3><p>A systematic literature search was conducted using electronic databases, including PubMed, Embase, Scopus, Web of Science, and Cochrane library, up to January 2024. The RCTs, evaluating the effects of propolis consumption on weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), waist-hip ratio (WHR), fat mass (FM), systolic BP (SBP), and diastolic BP (DBP), were included in the study. We used the random-effects model to establish the pooled effect size.</p></div><div><h3>Results</h3><p>A total of 22 RCTs involving 1082 participants were included in the study. Propolis supplementation demonstrated significant reductions in weight (weighted mean difference [WMD]: –0.37 kg; 95% confidence interval [CI]: –0.63 to –0.12), and BMI (WMD: –0.11 kg/m²; 95% CI: –0.13 to –0.09). However, there were no significant effects on WC, WHR, FM, HC, SBP, and DBP levels. The dose-response analysis revealed a significant nonlinear relationship between propolis dosage and WC (<em>P</em> = 0.020). Moreover, the BMI (<em>P</em> = 0.047) and WC (<em>P</em> = 0.004) reduction trend continues until 8 weeks of intervention and then this impact plateaued.</p></div><div><h3>Conclusions</h3><p>Supplementation with propolis seems to be effective in reducing weight and BMI. However, it should be noted that the anti-obesity properties of propolis supplementation were small and may not reach clinical importance. Therefore, future well-designed studies with a large sample size are needed to investigate the effect of propolis on body composition and BP in adults.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100754"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000249/pdfft?md5=f64243c8d10c41c97fab3a3e81ffe7c2&pid=1-s2.0-S0011393X24000249-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}